Ready to break up with cable news?
It started with the fear. Then the panic. Then you realized they needed you outraged more than informed.
Meet 1440’s Daily Digest: one daily newsletter covering 100+ sources, edited by hand. No algorithms. By humans. Just the facts, in a five-minute read. It's free, and 4+ million readers already start their day with it.
Fuel the Future of Psychedelic Journalism
Want to financially support original, independent reporting like this? You can! Donate at the link below, or just click the advertisement at the top of this article - no purchases or personal information sharing required
Weekly Psychedelic Policy Briefing: November 17, 2026
New Mexico reverses course on restrictive psilocybin rules, DEA rejects state cannabis registrations, and more
By Jack Gorsline

PSA’s Weekly Psychedelic Policy Briefing: November 17, 2026
In this week's edition of the Weekly Psychedelic Policy Briefing, Psychedelic State(s) of America examines major developments across federal research funding, state regulatory implementation and controlled substance enforcement. At the federal level, the U.S. Department of Health and Human Services committed nearly $25 million across two initiatives: up to $4.9 million through the Advanced Research Projects Agency for Health to Mark Cuban Cost Plus Drug Co. and Beond Inc. for ibogaine manufacturing and trial preparation, and a $20 million National Institute of Mental Health funding opportunity for rapid-acting psychotropics, including psilocybin and ketamine.
At the state level, the New Mexico Department of Health proposed major revisions to its draft medical psilocybin regulations following intense public pushback, scrapping mandatory in-person exams by separately certified clinicians and landlord sign-off requirements while cutting enrollment timelines and waiving permit fees. Meanwhile, the DEA issued show-cause rejection orders to medical cannabis businesses seeking federal Schedule III protections in five states and Washington, D.C., just as phase one of the federal hemp redefinition and Missouri's Intoxicating Cannabinoid Control Act took effect Nov. 12.
HHS Commits Nearly $25 Million to Ibogaine Development and Rapid-Acting Psychotropics Research
On Thursday, Nov. 12, 2026, HHS Secretary Robert F. Kennedy Jr. and Veterans Affairs Secretary Doug Collins announced up to $4.9 million over five years through the Advanced Research Projects Agency for Health (ARPA-H) to lay the regulatory, chemical and domestic manufacturing groundwork for U.S.-based ibogaine clinical trials targeting post-traumatic stress disorder and serious mental illnesses, with future awards planned for substance use disorders including opioid use disorder.
ARPA-H selected two performer teams under milestone-contingent agreements. Mark Cuban Cost Plus Drug Co., PBC was selected to establish the regulatory, clinical, chemical and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product, with HHS emphasizing that if development succeeds and earns Food and Drug Administration approval, the goal is to make the medicine available at production cost plus a fair margin. Beond Inc. – which owns and operates an Ibogaine clinic in Cancun, Mexico – was selected to deliver clinical data evaluating the safety, dosing, efficacy and durability of ibogaine to inform future controlled clinical development.
Both awardees must open-source their research findings. HHS noted that the initial awards fund Investigational New Drug preparation and clinical-grade supply rather than human-subject treatment or clinical trial authorization, citing ibogaine's known cardiac rhythm risks.
Simultaneously, the National Institute of Mental Health, led by Acting Director Andrea Beckel-Mitchener, published a $20 million Notice of Funding Opportunity to establish a research network studying rapid-acting psychotropic interventional drugs, explicitly encompassing ketamine, esketamine and psilocybin, with award recipients scheduled to be announced in summer 2027.
New Mexico Proposes Dropping In-Person Exams and Landlord Sign-Off From Draft Psilocybin Rules
Following significant community pushback, the New Mexico Department of Health proposed stripping two of the most controversial barriers from its draft medical psilocybin regulations (7.35.3 NMAC). Detailed in a Nov. 9 response to public comments from Deputy General Counsel Christopher D. Woodward to rulemaking Hearing Officer Craig Erickson, the proposed amendments—which are not yet finalized—respond to concerns that the initial draft would block access for rural residents, military veterans treated within the VA system, end-of-life patients and individuals in federally assisted housing.
Under the proposed revisions, the department eliminates the separate certifying clinician role, the mandatory six-month in-person medical exam and the controlled-substance registration requirement. Instead, treating practitioners will directly manage patient entry using a standardized screening tool, referring patients to medical providers only when specific contraindications or risks arise or if the patient has not seen a provider within 12 months. Regulators also proposed striking the requirement for healing centers and approved sites to obtain landlord sign-off, replacing it with property-owner or applicant risk attestations and patient acknowledgments of psilocybin's federal Schedule I status — a shift officials noted resolves potential conflicts with Section 8 housing. Additionally, the department proposes cutting maximum patient enrollment processing from 30 calendar days to 10 business days, waiving permit and application fees, relaxing group session staffing ratios to one practitioner per nine patients supported by one facilitator or qualified student per three, and clarifying that low-dose microdosing is permitted in approved settings, while maintaining its ban on vertical integration.
DEA Show-Cause Orders Target Medical Cannabis Registrants as Federal and Missouri Hemp Restrictions Take Effect
As reported by Marijuana Moment, the DEA issued nonpublic orders to show cause rejecting medical marijuana businesses applying for federal registration under 21 CFR 1301.13(k) and Schedule III protections in five states, California, Delaware, Illinois, North Dakota and Oregon, plus Washington, D.C.
In orders reviewed by news outlets, the DEA objected to co-located adult-use licensing, state regimes that allow dispensing without a written physician certification (specifically citing California and D.C.) and purported conflicts with U.S. treaty obligations under the Single Convention on Narcotic Drugs. Because the orders are proposed denials rather than final published agency actions, state-licensed operators face a late-November DEA sourcing deadline while contesting how federal registration standards apply to state-authorized dispensing models. On Capitol Hill, a Senate appropriations panel responded on Nov. 13 by proposing to extend federal protections for state medical marijuana programs without a House-passed anti-rescheduling provision, as reported by Marijuana Moment.
Simultaneously, phase one of the federal hemp redefinition entered into force on Thursday, Nov. 12, 2026, under Public Law 119-103 Section 2019 and P.L. 119-37 Section 781. Until Dec. 11, 2026, products containing cannabinoids not capable of being naturally produced by Cannabis sativa are excluded from the statutory definition of hemp and treated as marijuana under the Controlled Substances Act, ahead of the broader 0.3% total-THC standard and 0.4 mg-per-container cap scheduled for Dec. 11 unless Congress intervenes.
At the state level, Missouri's Intoxicating Cannabinoid Control Act (SS HCS HB 2641) also took effect on Nov. 12, construing specified hemp-derived cannabinoid products as marijuana and restricting sales to state-licensed dispensaries while providing a temporary exemption for beverages, as reported by Marijuana Moment. Separately, Nov. 13 marked the earliest eligible date for the DEA to publish a final order temporarily placing concentrated 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl into Schedule I (DEA-1570 / FR 2026-20943), though no final order had yet been published in the Federal Register as of press time.
Disclosures & Methodology
Psychedelic State(s) of America is an independent, nonpartisan investigative journalism initiative. Funding is provided via reader subscriptions and philanthropic research grants. The reporting presented in this briefing does not constitute medical, legal or investment advice. Primary source documents, administrative dockets, statutory texts and clinical trial registries are verified independently through official government portals, including HHS, GovInfo, Regulations.gov and ClinicalTrials.gov.
Key Documentation Tracker
HHS / ARPA-H Ibogaine Awards and NIMH Funding Opportunity: HHS Press Release, Nov. 12, 2026
New Mexico Medical Psilocybin Rulemaking (7.35.3 NMAC): NMDOH Response to Public Comments, Nov. 9, 2026
Federal Hemp Redefinition: Public Law 119-103
Missouri Intoxicating Cannabinoid Control Act: SS HCS HB 2641
DEA 7-OH Temporary Scheduling Notice: DEA-1570 / FR 2026-20943
Enjoyed this briefing? Subscribe to Psychedelic State(s) of America and share this briefing with someone who should read it.
Until next time,
The Psychedelic State(s) of America Team





